MiR‐130b demonstrated a stimulating effect on ESCC cell growth and aggressiveness by suppressing SASH1. It also promoted tumour formation in vivo by targeting SASH1. Our findings suggested that miR‐130b might contribute to the development of a miRNA‐based therapy for ESCC. Here, SASH1 is linked to neoplasm.